Clinuvel Pharmaceuticals Limited (CLVLF)
OTHER OTC:CLVLF
Want to see CLVLF full AI Analyst Report?
CLVLF Stock Chart & Stats
$7.23
-$0.52(-6.64%)
At close: 4:00 PM EST
$7.23
-$0.52(-6.64%)
Day’s Range― - ―
52-Week Range$5.79 - $8.93
Previous CloseN/A
Volume151.00
Average Volume (3M)121.00
Market Cap
$330.81M
Enterprise Value$423.38M
Total Cash (Recent Filing)$233.00M
Total Debt (Recent Filing)$341.09K
Price to Earnings (P/E)15.0
Beta0.30
Next Earnings
Sep 01, 2026EPS Estimate
0.35Next Dividend Ex-DateN/A
Dividend Yield0.42%
Share Statistics
EPS (TTM)0.14
Shares Outstanding50,427,900
10 Day Avg. Volume205
30 Day Avg. Volume121
Financial Highlights & Ratios
PEG Ratio0.00
Price to Book (P/B)2.16
Price to Sales (P/S)5.47
P/FCF Ratio12.74
Enterprise Value/Market Cap1.28
Enterprise Value/Revenue4.40
Enterprise Value/Gross Profit6.90
Enterprise Value/Ebitda10.16
Forecast
1Y Price Target
$14.72Price Target Upside103.60% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
EPS Forecast (FY)0.5
Revenue Forecast (FY)$70.31M
Bulls Say, Bears Say
Bulls Say
Strong Balance SheetA large cash position and two decades operating without debt give durable financial flexibility. Low leverage reduces refinancing and solvency risk, enabling self-funding of clinical programs, manufacturing scale-up and commercial expansion without reliance on dilutive or costly external financing.
Sustained ProfitabilityConsistent profitability across multiple periods demonstrates resilient unit economics and disciplined commercial execution. Profitability supports reinvestment into R&D and operations, lowers financing needs and signals that the core business model can generate free cash across business cycles.
Improving Market Access And ScaleRegulatory and commercial progress—expanded dosing allowance and broadening site coverage—structurally increase addressable usage and distribution capacity. These changes underpin sustainable volume growth and higher utilization of SCENESSE across approved markets over the medium term.
Bears Say
Rising Operating ExpensesMaterial expense growth—personnel, commercial distribution and R&D consumables—raises structural operating leverage. If revenue growth remains modest, sustained expense escalation can compress margins, increase cash burn volatility and reduce the pace at which investments translate into profitable scale.
Regulatory & Timing RiskSequential trial completion requirements and pending SEC/ADR feedback create durable timing uncertainty for key filings and market expansions. Delays in approvals or listings will postpone potential new‑indication revenues and heighten execution risk for the company's diversification strategy.
Single‑product ConcentrationRevenue dependence on one product concentrates commercial and reimbursement risk. Long‑term growth and resilience hinge on SCENESSE uptake, payer decisions and site access; any competitive, reimbursement or supply disruption could materially affect company cash flows and strategic flexibility.
Clinuvel Pharmaceuticals News
CLVLF FAQ
What was Clinuvel Pharmaceuticals Limited’s price range in the past 12 months?
Clinuvel Pharmaceuticals Limited lowest stock price was $5.79 and its highest was $8.93 in the past 12 months.
What is Clinuvel Pharmaceuticals Limited’s market cap?
Clinuvel Pharmaceuticals Limited’s market cap is $330.81M.
When is Clinuvel Pharmaceuticals Limited’s upcoming earnings report date?
Clinuvel Pharmaceuticals Limited’s upcoming earnings report date is Sep 01, 2026 which is in 136 days.
How were Clinuvel Pharmaceuticals Limited’s earnings last quarter?
Clinuvel Pharmaceuticals Limited released its earnings results on Feb 25, 2026. The company reported $0.141 earnings per share for the quarter, missing the consensus estimate of $0.201 by -$0.06.
Is Clinuvel Pharmaceuticals Limited overvalued?
According to Wall Street analysts Clinuvel Pharmaceuticals Limited’s price is currently Undervalued.
Does Clinuvel Pharmaceuticals Limited pay dividends?
Clinuvel Pharmaceuticals Limited pays a Annually dividend of $0.033 which represents an annual dividend yield of 0.42%. See more information on Clinuvel Pharmaceuticals Limited dividends here
What is Clinuvel Pharmaceuticals Limited’s EPS estimate?
Clinuvel Pharmaceuticals Limited’s EPS estimate is 0.35.
How many shares outstanding does Clinuvel Pharmaceuticals Limited have?
Clinuvel Pharmaceuticals Limited has 50,427,900 shares outstanding.
What happened to Clinuvel Pharmaceuticals Limited’s price movement after its last earnings report?
Clinuvel Pharmaceuticals Limited reported an EPS of $0.141 in its last earnings report, missing expectations of $0.201. Following the earnings report the stock price went down -6.143%.
Which hedge fund is a major shareholder of Clinuvel Pharmaceuticals Limited?
Currently, no hedge funds are holding shares in CLVLF
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Clinuvel Pharmaceuticals Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$14.72 (103.60% Upside)
$14.72 (103.60% Upside)
Blogger Sentiment
Bullish
CLVLF Sentiment 93%
Sector Average ―
Sector Average ―
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
4.09%
12-Months-Change
Fundamentals
Return on Equity
13.29%
Trailing 12-Months
Asset Growth
22.98%
Trailing 12-Months
Company Description
Clinuvel Pharmaceuticals Limited
Clinuvel Pharmaceuticals Limited, a biopharmaceutical company, focuses on developing and commercializing treatments for patients with genetic, metabolic, and life-threatening disorders in Australia, Europe, the United States, Switzerland, and internationally. Its lead drug candidate is SCENESSE, a systemic photoprotective drug for the prevention of phototoxicity in adult patients with erythropoietic protoporphyria (EPP). The company's pipeline products include CUV9900, an alpha-melanocyte stimulating hormone analogue; Parvysmelanotide (VLRX001), which provoke prolonged cellular activity; and PRÉNUMBRA, a liquid injectable formulation of afamelanotide. Clinuvel Pharmaceuticals Limited has a collaboration agreement with HK Winhealth Pharma Group Co. Limited t to treat EPP patients with SCENESSE under a named patient program in the People's Republic of China. The company was founded in 1987 and is headquartered in Melbourne, Australia.
CLVLF Company Deck
CLVLF Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call conveys a generally positive outlook driven by modest revenue growth, record first-half sales, strong cash reserves and sustained profitability while management deliberately invests in in-house R&D, clinical and manufacturing capabilities. Those positives are tempered by materially higher operating expenses across personnel, R&D and corporate areas, a non-cash FX translation loss, and timing/uncertainty around regulatory filings (CUV107 completion required before submission) and the NASDAQ ADR uplift. On balance, the company emphasizes that expense increases are strategic investments supported by a strong balance sheet and cash runway.View all CLVLF earnings summariesCLVLF Stock 12 Month Forecast
Average Price Target
$14.72
▲(103.60% Upside)
Technical Analysis
Acrux
―
Starpharma Holdings Limited
―
PYC Therapeutics Limited
―
Botanix Pharmaceuticals Limited
―
Biome Australia Ltd
―
Ownership Overview
―
Insiders
2.82% Mutual Funds
― Other Institutional Investors
95.44% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---